

CORRESPONDENCE



Effect of Vaccination on Household Transmission of SARS-CoV-2 in England

TO THE EDITOR: Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevents infection and reduces the severity of coronavirus disease 2019 (Covid-19) in vaccinated persons.^{1,2} We investigated whether vaccination would reduce transmission in the household setting in the context of postvaccination infection.

We analyzed data from the Household Transmission Evaluation Dataset (HOSTED), which has information on all laboratory-confirmed cases of Covid-19 in England and in which data on all persons sharing the same address are linked.³ We then linked to individual-level data on all Covid-19 vaccinations in England (see the Methods section in the Supplementary Appendix, available with the full text of this letter at NEJM.org).

We compared the risk of secondary infection (defined as a positive SARS-CoV-2 test 2 to 14 days after the positive test for the index case) among unvaccinated household contacts of persons with SARS-CoV-2 infection who had received at least one dose of the ChAdOx1 nCoV-19 or BNT162b2 vaccine 21 days or more before testing positive with the risk among unvaccinated household contacts of unvaccinated persons with infection. We fitted logistic-regression models with adjustment for the age and sex of the person with the index case of Covid-19 (index patient) and the household contact, geographic region, calendar week of the index case, deprivation (a composite score of socioeconomic and other factors), and household type and size. We also considered the timing of effects among index patients who had been vaccinated at any time up to the date of the positive test.

Between January 4 and February 28, 2021, there were 960,765 household contacts of unvaccinated index patients, and there were 96,898 secondary cases of Covid-19 (10.1%). (Descriptive data regarding the index patients and their household contacts are provided in the Summary Results section.) The numbers of secondary cases according to the vaccination status of the index patient, and the results of logistic-regression models, are shown in Table 1. Overall, the likelihood of household transmission was approximately 40 to 50% lower in households of index patients who had been vaccinated 21 days or more before testing positive than in households of unvaccinated index patients; the findings were similar for the two vaccines. Most of the vaccinated index patients in our data set (93%) had received only the first dose of vaccine. Assessment of infection risks among household contacts according to the timing of vaccination of the index patient showed protective effects when the vaccine had been administered at least

THIS WEEK'S LETTERS

- 759 **Effect of Vaccination on Household Transmission of SARS-CoV-2 in England**
- 761 **Lorlatinib in a Child with *ALK*-Fusion-Positive High-Grade Glioma**
- 764 **Aspirin Dosing in Cardiovascular Disease**
- 766 **Hypothermic Machine Perfusion in Liver Transplantation**
- 768 **Adrenal Incidentaloma**

Table 1. Numbers of Household Contacts and Secondary Cases of Covid-19, According to Vaccination Status of Index Patient, and Adjusted Odds Ratios.*

Vaccination Status of Index Patient	Household Contacts	Secondary Cases	Adjusted Odds Ratio (95% CI)
	<i>no.</i>	<i>no. (%)</i>	
Not vaccinated before testing positive	960,765	96,898 (10.1)	Reference
Vaccinated with ChAdOx1 nCoV-19 vaccine ≥ 21 days before testing positive	3,424	196 (5.7)	0.52 (0.43–0.62)
Vaccinated with BNT162b2 vaccine ≥ 21 days before testing positive	5,939	371 (6.2)	0.54 (0.47–0.62)

* Odds ratios were adjusted for the age and sex of the index patient and their household contact, geographic region, calendar week of the index case, and an index of multiple deprivation and household type and size. CI denotes confidence interval, and Covid-19 coronavirus disease 2019.

14 days before the positive test (Figs. S1 and S2 in the Supplementary Appendix).

HOSTED does not include data on symptoms or cycle-threshold values and has information only on diagnosed cases. Among index patients, those who had been vaccinated were likely to be less severely symptomatic² and might have been less infectious than those who were unvaccinated.⁴ Studies that involved active follow-up of contacts and that used serologic testing have shown higher rates of household transmission than were observed in our study⁵; bias could occur if case ascertainment differed between household contacts of vaccinated persons and those of unvaccinated persons. Our findings with respect to the timing of vaccination of index patients are consistent with previous data regarding the timing of individual protection after vaccination¹ and thus support the overall findings. There may have been misclassification of index and secondary cases, which are determined on the basis of testing dates; however, such misclassification would tend to attenuate the estimated protective effect of vaccination. Data are needed to inform the reduction in transmissibility of the virus after the receipt of two vaccine doses. It will be important to consider these findings alongside other emerging evidence to inform the benefits of vaccination.

Ross J. Harris, Ph.D.

Public Health England
London, United Kingdom
feedback.c19epi@phe.gov.uk

Jennifer A. Hall, Ph.D.

University College London Institute for Women's Health
London, United Kingdom

Asad Zaidi, M.Sc.

Nick J. Andrews, Ph.D.

J. Kevin Dunbar, M.B., Ch.B.

Gavin Dabrera, M.B., B.S., F.F.P.H.

Public Health England
London, United Kingdom

Drs. Dunbar and Dabrera contributed equally to this letter.

The Household Transmission Evaluation Dataset (HOSTED) surveillance system was reviewed and approved by the Public Health England Research Ethics Governance Group. The data were collected and linked by NHS Digital. The data were processed lawfully under General Data Protection Regulation Article 6(1)e and 9(2)i and shared under Regulation 3 of the Health Service (Control of Patient Information) Regulations 2002.

Supported by Public Health England.

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

This letter was published on June 23, 2021, at NEJM.org.

1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med* 2020;383:2603-15.
2. Bernal JL, Andrews N, Gower C, et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. March 2, 2021 (<https://www.medrxiv.org/content/10.1101/2021.03.01.21252652v1>). preprint.
3. Hall JA, Harris RJ, Zaidi A, Woodhall SC, Dabrera G, Dunbar JK. HOSTED — England's Household Transmission Evaluation Dataset: preliminary findings from a novel passive surveillance system of COVID-19. *Int J Epidemiol* 2021 April 9 (Epub ahead of print).
4. Levine-Tiefenbrun M, Yelin I, Katz R, et al. Decreased SARS-CoV-2 viral load following vaccination. February 8, 2021 (<http://medrxiv.org/content/early/2021/02/08/2021.02.06.21251283>). preprint.
5. Public Health England. SARS-CoV2 susceptibility and transmission risk in children: an overview of current evidence from PHE surveillance work, 19 August 2020. 2020 (<https://www.gov.uk/government/publications/phe-sars-cov2-susceptibility-and-transmission-risk-in-children-an-overview-of-current-evidence-from-phe-surveillance-work-19-august-2020>).

DOI: 10.1056/NEJMc2107717